-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Mydecine Innovations Group Reports Q2 Financial Results And Management Updates
Mydecine Innovations Group Reports Q2 Financial Results And Management Updates
After the resignation of several key board members on August 12, Mydecine Innovations Group (OTC:MYCOF) reported its financial results.
For the period corresponding to the six months ended June 30, 2022:
-
Total cash was $324,146
-
Net loss due to common stockholders was $8.09 million from operations, or a basic and diluted loss per share of $(1.31), compared to net loss from operations of $13.53 million, or a basic and diluted loss per share of ($3.04) for the same period of 2021.
-
R&D expenses for the six-month period totaled $1,702,011, compared to $1,322,130 for the same period in 2021.
-
R&D expenses for the three-month period totaled $652,486, compared to $1,091,920 for the same period in 2021.
In relation to the last category of expenses, Mydecine announced the start of a government-funded trial testing its proprietary, FDA-approved psilocybin-based MYCO-001 for tobacco addiction in June. In July, the company filed a patent application for MYCO-006, their family of novel short-acting MDMA analogs.
The apparently sudden resignation of the company's designated directors Damon Michaels, Josephine Wu, Dr. Saeid Babaei and Dr. Victoria Hale was announced on Friday, together with the launch of a search for candidates with knowledge of drug development to fill two board positions, as Michaels will remain as the company's COO.
The three remaining board members are Josh Bartch, Rob Roscow and Todd Heinzl.
According to Mydecine's statements, "The departures are part of a larger organizational shift that will allow the corporation to concentrate on its core competencies with more efficiency."
Photo by Sean Pollock on Unsplash
After the resignation of several key board members on August 12, Mydecine Innovations Group (OTC:MYCOF) reported its financial results.
后几名主要董事会成员辞职8月12日,Mydecine创新集团(场外交易代码:MYCOF)报告了其财务业绩。
For the period corresponding to the six months ended June 30, 2022:
截至2022年6月30日止六个月的期间:
-
Total cash was $324,146
-
Net loss due to common stockholders was $8.09 million from operations, or a basic and diluted loss per share of $(1.31), compared to net loss from operations of $13.53 million, or a basic and diluted loss per share of ($3.04) for the same period of 2021.
-
R&D expenses for the six-month period totaled $1,702,011, compared to $1,322,130 for the same period in 2021.
-
R&D expenses for the three-month period totaled $652,486, compared to $1,091,920 for the same period in 2021.
-
现金总额是324,146美元
-
净亏损由于普通股股东的亏损为809万美元,或每股基本和稀释后亏损1.31美元,而2021年同期运营净亏损1353万美元,或每股基本和稀释后亏损3.04美元。
-
研发费用这六个月的收入总额为1 702 011美元,而2021年同期为1 322 130美元。
-
研发费用这三个月的收入总额为652,486美元,而2021年同期为1,091,920美元。
In relation to the last category of expenses, Mydecine announced the start of a government-funded trial testing its proprietary, FDA-approved psilocybin-based MYCO-001 for tobacco addiction in June. In July, the company filed a patent application for MYCO-006, their family of novel short-acting MDMA analogs.
关于最后一类费用,Mydecine宣布在6月份开始一项由政府资助的试验,测试其专有的、FDA批准的基于裸盖菇素的myco-001治疗烟草成瘾。今年7月,该公司为他们的新型短效MDMA类似物Myco-006申请了专利。
The apparently sudden resignation of the company's designated directors Damon Michaels, Josephine Wu, Dr. Saeid Babaei and Dr. Victoria Hale was announced on Friday, together with the launch of a search for candidates with knowledge of drug development to fill two board positions, as Michaels will remain as the company's COO.
这个公司指定董事显然突然辞职达蒙·迈克尔斯、约瑟芬·吴、赛义德·巴巴伊博士和维多利亚·黑尔博士于周五宣布,同时开始寻找具有药物开发知识的候选人来填补两个董事会职位,迈克尔斯将继续担任公司的首席运营官。
The three remaining board members are Josh Bartch, Rob Roscow and Todd Heinzl.
剩下的三名董事会成员是乔什·巴奇、罗布·罗斯考和托德·海因茨尔。
According to Mydecine's statements, "The departures are part of a larger organizational shift that will allow the corporation to concentrate on its core competencies with more efficiency."
根据Mydecine的陈述,这些离职是更大的组织转变的一部分,这将使公司能够更有效地专注于其核心能力。“
Photo by Sean Pollock on Unsplash
肖恩·波洛克在Unspash上的照片
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧